Related Experiment Video
Updated: May 25, 2026
07:39
Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens
Published on: June 23, 2022
Radioligand Therapy Hormone Combinations and the ENZA-p Trial
1Theranostics and Nuclear medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia; Garvan Institute of Medical Research.
European Urology Focus
|May 23, 2026
Summary
Combining androgen blockade with PSMA radioligand therapy improves survival in metastatic prostate cancer. Understanding the androgen and PSMA receptor relationship is key to optimizing treatments for prostate cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Radiopharmaceutical Therapy
Background:
- The androgen axis is a critical driver in prostate cancer progression.
- Androgen blockade is a standard treatment for metastatic prostate cancer.
- Prostate-specific membrane antigen (PSMA) radioligand therapy is emerging for metastatic castration-resistant prostate cancer (mCRPC).
Purpose of the Study:
- To investigate the relationship between androgen receptor signaling and PSMA expression in mCRPC.
- To understand the clinical impact of androgen blockade on PSMA expression.
- To explore the potential of combining androgen blockade with PSMA-targeted therapies.
Main Methods:
- Review of preclinical data on androgen/PSMA receptor interactions.
- Analysis of translational data from the ENZA-p randomized phase 2 trial.
- Discussion of PSMA receptor genetics and expression changes in response to enzalutamide.
Main Results:
- Preclinical studies show a strong link between androgen and PSMA receptors in prostate cancer.
- The ENZA-p trial demonstrated improved survival and quality of life with enzalutamide plus [177Lu]Lu-PSMA-617 compared to enzalutamide alone.
- Androgen blockade influences PSMA expression, with implications for treatment efficacy.
Conclusions:
- The combination of androgen blockade and PSMA radioligand therapy offers significant benefits for mCRPC patients.
- Understanding the interplay between androgen and PSMA receptors is crucial for refining treatment strategies.
- Further research into PSMA expression dynamics under androgen deprivation is warranted.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...